On the other hand, if the court rules against Hikma, that would be a big worry for every generic drug maker.

The idea that you can have a case go with very little evidence about what has been said to induce infringement will mean that it's really easy to bring litigation against these generic companies.

If they lose...

The ramifications for being found guilty of induced infringement are really significant.

It's treble damages, so it's three times the amount that the company would have made but for the introduction of the generic drug.